Leuconostoc mesenteroides cJLM119 strain and food fermentation composition containing culture thereof
Through the fermentation of the CJLM119 strain of the enterometaphylla CJLM119, a composition with immune enhancement and intestinal health improvement effects was generated, which solved the shortcomings of existing fermented foods in immunity and intestinal health and achieved significant health benefits.
Patent Information
- Application Number
- CN202280084526.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-10-31
- Filing Date
- 2022-11-29
- Publication Date
- 2024-11-12
AI Technical Summary
Existing fermented foods are difficult to effectively enhance the immune system and improve intestinal health, especially through the fermentation of lactic acid bacteria, which fails to fully utilize the potential health benefits of mesophylla samsara.
Fermentation is performed using the strain of the entero-membrane CJLM119 or its culture to produce compositions with immune enhancement and intestinal health improvement effects, including its lysates, extracts or derivative components, for the preparation of various fermented foods and Health food.
Significantly enhance the immune response, improve the balance of intestinal flora, inhibit the growth of harmful bacteria, improve the health of the intestinal tract, enhance cell viability and secretion of immune mediators, such as the expression of TNF-α and IL-6.
Smart Images

Figure CN118946277A_ABST
Abstract
Description
[Technical field]
[0001] The present invention relates to a composition for enhancing immunity or improving intestinal health, which is fermented with a composition for fermentation, wherein the composition for fermentation comprises any one or more selected from Leuconostoc mesenteroides CJLM119 strain or its culture, and comprises any one or more selected from the culture of Leuconostoc mesenteroides CJLM119 strain, its lysate, its extract or its derived components. [Background Technology]
[0002] Fermented food refers to food or beverages whose ingredients are transformed by the growth of specific microorganisms and the action of enzymes. It is reported that beneficial bacteria including lactic acid bacteria improve the bioavailability of nutrients by transforming the chemical components that make up food ingredients during the fermentation process, enhance food safety as a biological preservative, decompose toxic substances and nutritional inhibitors, and produce bioactive substances (Tamang JP et al., Front Microbiol (2016), 7, 578.).
[0003] Among lactic acid bacteria, Leuconostoc mesenteroides is known to be a representative lactic acid bacterium involved in lactic acid fermentation of vegetables and is found in fermented vegetables such as kimchi. [Summary of the invention]
[0004] [Technical issues]
[0005] The present invention provides a composition for enhancing immunity or improving intestinal health, which is fermented with a composition for fermentation, wherein the composition for fermentation comprises any one or more selected from the intestinal mesenteroides CJLM119 strain or its culture, and comprises any one or more selected from the intestinal mesenteroides CJLM119 strain culture, its lysate, its extract or its derived components.
[0006] [Technical solution]
[0007] An object of the present invention is to provide a composition for fermentation, comprising any one or more selected from the group consisting of Leuconostoc mesenteroides CJLM119 strain or a culture thereof.
[0008] Another object of the present invention is to provide a food composition for immunity enhancement, comprising a fermentation product fermented with the Leuconostoc mesenteroides CJLM119 strain or a culture thereof.
[0009] Another object of the present invention is to provide a food composition for improving intestinal health, comprising a fermentation product fermented with the Leuconostoc mesenteroides CJLM119 strain or a culture thereof.
[0010] Another object of the present invention is to provide a health functional food for immune enhancement, comprising a fermentation product fermented with the Leuconostoc mesenteroides CJLM119 strain or a culture thereof.
[0011] Another object of the present invention is to provide a health functional food for improving intestinal health, which comprises a fermentation product fermented with the Leuconostoc mesenteroides CJLM119 strain or a culture thereof.
[0012] Another object of the present invention is to provide a method for increasing the immune enhancement effect of a composition, which comprises fermenting the composition with the Leuconostoc mesenteroides CJLM119 strain or a culture thereof.
[0013] Another object of the present invention is to provide a method for increasing the intestinal health improvement effect of a composition, which comprises fermenting the composition with the Leuconostoc mesenteroides CJLM119 strain or a culture thereof.
[0014] [Beneficial Effects]
[0015] The composition of the invention has the effects of enhancing immunity and improving intestinal health. [Drawings]
[0016] Figure 1 The results of detecting cytotoxicity after treating J774A.1 cells (which are mouse immune cells) with the fermentation compositions of Preparation Examples 1 to 3 and Comparative Examples 1 and 2 are shown;
[0017] Figure 2 The figure shows a 5×10 6 cfu / mL (fermentation composition A), 10 6 cfu / mL (fermentation composition B) and 5×10 5 cfu / mL (fermentation composition C) The fermentation composition of Leuconostoc mesenteroides CJLM119 strain and its supernatant were used to treat J774A.1 cells (which are mouse immune cells) and then the cytotoxicity was detected;
[0018] Figure 3 The example shows a 1.25×10 6 cfu / mL and 6.25×10 6 cfu / mL The fermentation composition of Leuconostoc mesenteroides CJLM119 or KCTC 3505 strain was used to treat J774A.1 cells (which are mouse immune cells) and detect the cytotoxicity results;
[0019] Figure 4 The example shows a 1.25×10 6 cfu / mL, 2.5×10 6cfu / mL and 5.0×10 6 cfu / mL The fermentation composition of Leuconostoc mesenteroides CJLM119 or KCTC 3505 strain was used to treat J774A.1 cells (which are mouse immune cells) and detect the cytotoxicity results;
[0020] Figure 5 The analysis results of the expression level of TNF-α (tumor necrosis factor-α) in J774A.1 cells (which are mouse immune cells) treated with the fermentation compositions of Preparation Examples 1 to 3 and Comparative Examples 1 and 2 are shown (***p<0.001);
[0021] Figure 6 The analysis results of IL-6 (interleukin-6) expression levels in J774A.1 cells (which are mouse immune cells) treated with the fermentation compositions of Preparation Examples 1 to 3 and Comparative Examples 1 and 2 are shown (***p<0.001);
[0022] Figure 7 The figure shows a 5×10 6 cfu / mL, 10 6 cfu / mL and 5×10 5 cfu / mL The results of the analysis of the expression level of TNF-α after the fermentation composition of Leuconostoc mesenteroides CJLM119 strain was used to treat J774A.1 cells (which are mouse immune cells) (***p<0.001, **p<0.01);
[0023] Figure 8 Shown is a 5×10 6 cfu / mL, 10 6 cfu / mL and 5×10 5 cfu / mL The results of the analysis of the expression level of IL-6 after the fermentation composition of Leuconostoc mesenteroides CJLM119 strain was used to treat J774A.1 cells (which are mouse immune cells) (***p<0.001, **p<0.01);
[0024] Fig. 9 The example shows a 1.25×10 6 cfu / mL and 6.25×10 6 cfu / mL The results of analysis of the expression level of TNF-α after J774A.1 cells (which are mouse immune cells) were treated with the fermentation composition of Leuconostoc mesenteroides CJLM119 or KCTC 3505 strain (***p<0.001, ##p<0.01, #p<0.05);
[0025] Fig.10 The example shows a 1.25×10 6cfu / mL, 2.5×10 6 cfu / mL and 5.0×10 6 cfu / mL The results of analysis of the expression level of TNF-α after treating J774A.1 cells (which are mouse immune cells) with the fermentation composition of Leuconostoc mesenteroides CJLM119 or KCTC 3505 strain (**p<0.01, *p<0.05);
[0026] Fig.11 The example shows a 1.25×10 6 cfu / mL and 6.25×10 6 cfu / mL The results of analysis of the expression level of IL-6 after J774A.1 cells (which are mouse immune cells) were treated with the fermentation composition of Leuconostoc mesenteroides CJLM119 or KCTC 3505 strain (***p<0.001, ##p<0.01, #p<0.05);
[0027] Fig.12 The example shows a 1.25×10 6 cfu / mL, 2.5×10 6 cfu / mL and 5.0×10 6 cfu / mL of the fermentation composition of Leuconostoc mesenteroides CJLM119 or KCTC 3505 strain to treat J774A.1 cells (which are mouse immune cells) after the IL-6 expression level was analyzed (***p<0.001, **p<0.01, *p<0.05); and
[0028] Fig.13 The results of comparison of the effect of the fermentation composition of Preparation Example 4 on inhibiting the growth of harmful bacteria are shown. Terms: fermentation composition, fermentation; supernatant of fermentation composition, metabolite. [Specific implementation method]
[0029] The present invention is explained in detail as follows. At the same time, each description and embodiment disclosed in the present invention can also be applied to other descriptions and embodiments. That is to say, all combinations of the elements disclosed in the present invention fall within the scope of the present invention. In addition, the scope of the present invention is not limited by the following specific description. In addition, reference is made to many papers and patent documents, and citations are pointed out throughout this specification. The disclosures of the cited papers and patent documents are incorporated into this specification by reference as a whole, to more clearly explain the content of the present invention and the level of the technical field to which the present invention belongs.
[0030] One aspect of the present invention provides a composition for fermentation, comprising any one or more selected from the group consisting of Leuconostoc mesenteroides CJLM119 strain or a culture thereof.
[0031] The strain of the present invention can be a strain of the genus Leuconostoc sp., in particular Leuconostoc sp., more particularly Leuconostoc sp. CJLM119 strain (US2019-0297908A1) with a preservation number of KCTC 13043BP.
[0032] In the present invention, the term "culture" may refer to the entire culture medium, which contains the strain of the present invention, its metabolites, additional nutrients, etc., and is obtained by culturing the strain in a culture medium capable of providing nutrients for a period of time so that the strain can grow and survive in a test tube. "Culture" is a composition containing a strain, and in the present invention, the culture can be used for the same purpose as the strain. In the present invention, the term "culture" can be used interchangeably with "culture fluid", "culture supernatant", "conditioned culture fluid" or "conditioned medium".
[0033] In the present invention, the term "culture" refers to the cultivation of microorganisms under appropriately controlled environmental conditions. The cultivation process of the present invention can be carried out according to suitable culture media and culture conditions known in the art. Those skilled in the art can easily adjust and use the cultivation process according to the selected strain. Specifically, the cultivation can be a batch, continuous or fed-batch process, but is not limited thereto.
[0034] The carbon source contained in the culture medium may include sugars and carbohydrates (such as glucose, sucrose, lactose, fructose, maltose, starch and cellulose), oils and fats (such as soybean oil, sunflower oil, castor oil and coconut oil), fatty acids (such as palmitic acid, stearic acid and linoleic acid), alcohols (such as glycerol and ethanol) and organic acids (such as acetic acid), which can be used alone or in combination, but the carbon source is not limited thereto.
[0035] The nitrogen source contained in the culture medium may include an organic nitrogen source (such as peptone, yeast extract, broth, malt extract, corn steep liquor and soybean meal) and an inorganic nitrogen source (such as urea, ammonium sulfate, ammonium chloride, ammonium phosphate, ammonium carbonate and ammonium nitrate), which may be used alone or in combination, but the nitrogen source is not limited thereto.
[0036] The phosphorus source contained in the culture medium may include monopotassium phosphate, dipotassium phosphate, monosodium phosphate, and disodium phosphate, but is not limited thereto.
[0037] The culture medium may contain metal salts (such as magnesium sulfate or iron sulfate) as well as amino acids, vitamins and appropriate precursors. These culture media or precursors may be added to the culture in a batch or continuous manner, but are not limited thereto.
[0038] During the culture, chemicals such as ammonium hydroxide, potassium hydroxide, ammonia, phosphoric acid and sulfuric acid can be added to the culture in an appropriate manner to regulate the pH of the culture. During the culture, defoamers such as fatty acid polyglycol esters can be used to suppress foam generation. Oxygen or oxygen-containing gas can be injected into the culture to maintain the aerobic state of the culture, or gas can be not injected, or nitrogen, hydrogen or carbon dioxide gas can be injected to maintain anaerobic and microaerobic states.
[0039] The culture can be obtained by culturing the strain of the present invention at 10 to 40°C for 6 to 48 hours, for example, at 20 to 40°C for 12 to 36 hours, or at 30 to 40°C for 16 to 24 hours.
[0040] The culture of the present invention may include a live culture (i.e., a product obtained by culturing live bacteria in a culture medium), a culture obtained by killing live bacteria in a live culture, a culture filtrate (i.e., a product obtained by removing dead or live bacteria from a culture), and a concentrated or lyophilized product thereof.
[0041] The culture filtrate can be obtained by leaving the culture broth to stand for a certain period of time and taking only the upper layer of liquid without taking the portion precipitated in the lower layer, removing bacteria by filtration, or by centrifuging the culture broth to remove the bottom precipitate and taking only the upper layer of liquid. In the present invention, "culture filtrate" can be used interchangeably with "supernatant".
[0042] The bacteria can be obtained by centrifuging the culture solution and taking out the portion precipitated in the lower layer, or by leaving the culture solution at rest for a certain period of time and then removing the upper liquid layer, because the bacteria sink to the lower layer of the culture solution by gravity.
[0043] The concentrate can be obtained by concentrating the culture broth of the strain itself or the supernatant obtained by centrifugation or filtration using a culture broth filter.
[0044] The lyophilized product can be obtained by lyophilizing the strain culture solution itself or the culture solution.
[0045] The composition for fermentation of the present invention may be used for producing various fermented foods, and may be specifically used for fermenting condiments such as garlic, red pepper powder, and spices, but is not limited thereto.
[0046] In the case of fermentation using the composition for fermentation of the present invention, food having an immunity enhancing effect and / or an intestinal health improving effect may be produced, but is not limited thereto.
[0047] Another aspect of the present invention provides a food composition for immunity enhancement, comprising a fermentation product fermented with the Leuconostoc mesenteroides CJLM119 strain or a culture thereof.
[0048] Another aspect of the present invention provides a food composition for improving intestinal health, comprising a fermentation product fermented with the Leuconostoc mesenteroides CJLM119 strain or a culture thereof.
[0049] The strain and culture of Leuconostoc mesenteroides CJLM119 were as described above.
[0050] The food composition of the present invention may include a fermented product fermented with the composition for fermentation of the aforementioned aspects. For example, the fermented product may include a fermented product fermented with a mesenteroides-like leuconostoc CJLM119 strain or a culture thereof. Alternatively, the fermented product may include the following fermented product, wherein the fermented product fermented with a mesenteroides-like leuconostoc CJLM119 strain or a culture thereof is further fermented.
[0051] In an exemplary embodiment of the present invention, the food composition of the present invention may include garlic, red pepper powder, a nitrogen source, and the like fermented with the composition for fermentation of the aforementioned aspects.
[0052] As used herein, the term "fermentation" refers to any activation or process involving the enzymatic or metabolic breakdown of organic matter using microorganisms.
[0053] In the present invention, the term "fermentation product" refers to a product obtained by enzymatic or metabolic decomposition accompanied by fermentation using a microorganism. For example, the fermentation product may be in liquid form. In addition, the fermentation product may be a crude solution of the obtained fermentation product or its supernatant.
[0054] In another exemplary embodiment of the present invention, the fermented product of the present invention may comprise live bacteria.
[0055] In another exemplary embodiment of the present invention, the fermented product of the present invention can be subjected to additional fermentation. For example, the fermented product of the present invention can be added to vegetables and the like and subjected to additional fermentation, or can be added to a liquid composition and the like and subjected to additional fermentation. Examples of vegetables include cabbage and radish, but are not limited thereto.
[0056] The fermented product of the present invention may be a product fermented at 25° C. to 40° C. using any one or more selected from the strains of the present invention or their cultures. The fermented product of the present invention may be a product fermented for 10 to 30 hours using any one or more selected from the strains of the present invention or their cultures.
[0057] For example, the temperature during fermentation of the present invention may be within a range consisting of a lower limit and / or an upper limit, the lower limit being selected from 25° C. or higher, 27° C. or higher, 28° C. or higher, and 29° C. or higher, and the upper limit being selected from 40° C. or lower, 35° C. or lower, 33° C. or lower, and 31° C. or lower. The time during fermentation of the present invention may be within a range consisting of a lower limit and / or an upper limit, the lower limit being selected from 10 hours or more, 12 hours or more, 14 hours or more, 16 hours or more, and 18 hours or more, and the upper limit being selected from 30 hours or less, 28 hours or less, 27 hours or less, 26 hours or less, and 25 hours or less.
[0058] The fermented product of the present invention may be a product in which a composition comprising any one or more selected from garlic, red pepper powder and a nitrogen source is fermented. As an exemplary embodiment, the composition to be fermented of the present invention may be a composition comprising any one or more selected from garlic, red pepper powder and a nitrogen source, but is not limited thereto. As another exemplary embodiment, the fermented product of the present invention may be obtained by adding the strain of the present invention and / or its culture to a composition comprising any one or more selected from garlic, red pepper powder and a nitrogen source and fermenting the composition.
[0059] The fermented product of the present invention can be obtained by adding 0.5 wt % to 4 wt % of the strain of the present invention and / or its culture, relative to the total weight of the composition comprising any one or more selected from garlic, red pepper powder and a nitrogen source.
[0060] As an example, the strain of the present invention and / or its culture may be contained within a range consisting of a lower limit and / or an upper limit selected from 1 wt % or more, 1.2 wt % or more, 1.6 wt % or more and 1.8 wt % or more, relative to the total weight of the composition, and an upper limit selected from 3.5 wt % or less, 2.8 wt % or less, 2.6 wt % or less and 2.2 wt % or less.
[0061] Relative to the gross weight of the composition, the fermented product of the present invention may be a product wherein a composition comprising 4 to 10 wt % of garlic is fermented. As an exemplary embodiment, the composition to be fermented of the present invention may be a composition comprising any one or more selected from garlic, red pepper powder, and a nitrogen source, but is not limited thereto. As another exemplary embodiment, relative to the gross weight of the composition, the composition to be fermented of the present invention (which comprises any one or more selected from garlic, red pepper powder, and a nitrogen source) may comprise 4 to 10 wt % of garlic.
[0062] As an example, garlic can be contained within a range consisting of a lower limit selected from 4 wt % or more, 5 wt % or more, 6 wt % or more, and 6.5 wt % or more and / or an upper limit selected from 10 wt % or less, 9 wt % or less, 8 wt % or less, and 7.5 wt % or less, relative to the total weight of the composition.
[0063] Garlic may be included in the composition of the present invention in the form of minced garlic, extracts, concentrates, powders, etc., but is not limited thereto, and commercially available garlic and products processed in the form of minced garlic, extracts, concentrates, powders, etc. may be used without limitation.
[0064] As another exemplary embodiment, the composition to be fermented of the present invention (which comprises any one or more selected from garlic, red pepper powder and a nitrogen source) may comprise 0.5 wt % to 4 wt % of red pepper powder relative to the total weight of the composition.
[0065] As an example, red pepper powder can be contained within a range consisting of a lower limit and / or an upper limit, relative to the total weight of the composition, the lower limit being selected from 0.5 wt % or more, 1 wt % or more, 1.2 wt % or more, 1.6 wt % or more, and 1.8 wt % or more, and the upper limit being selected from 4 wt % or less, 3.5 wt % or less, 2.8 wt % or less, 2.6 wt % or less, and 2.2 wt % or less.
[0066] As the red pepper powder, pepper may be dried and then ground, or freeze-dried and made into powder, but the red pepper powder is not limited thereto, and commercially available red pepper powder may be used without limitation.
[0067] As another exemplary embodiment, the composition to be fermented of the present invention (which comprises any one or more selected from garlic, red pepper powder, and a nitrogen source) may comprise 0.1 wt % to 1.5 wt % of a nitrogen source relative to the total weight of the composition.
[0068] As an example, the nitrogen source can be contained within a range consisting of a lower limit and / or an upper limit, relative to the total weight of the composition, the lower limit being selected from 0.3 wt % or more, 0.6 wt % or more, 0.9 wt % or more, and 1.1 wt % or more, and the upper limit being selected from 1.45 wt % or less, 1.4 wt % or less, 1.35 wt % or less, and 1.3 wt % or less.
[0069] The nitrogen source may be edible. The nitrogen source may be a seasoning, for example, (CJ CheilJedang), but not limited to this.
[0070] In particular, the composition of the present invention may comprise garlic.
[0071] The fermented product of the present invention may be a product in which a composition further comprising any one or more selected from a carbon source or a salt is fermented.
[0072] In an exemplary embodiment, the composition to be fermented of the present invention may contain 2 to 4 wt % of a carbon source relative to the total weight of the composition.
[0073] As an example, the carbon source can be contained within a range consisting of a lower limit and / or an upper limit, relative to the total weight of the composition, the lower limit being selected from 2.2 wt % or more, 2.4 wt % or more, 2.6 wt % or more and 2.8 wt % or more, and the upper limit being selected from 3.8 wt % or less, 3.6 wt % or less, 3.4 wt % or less and 3.2 wt % or less.
[0074] The carbon source may be edible. The carbon source may be fructose, sucrose, glucose, etc., such as fructose, specifically crystalline fructose, but not limited thereto.
[0075] As an exemplary embodiment, the composition to be fermented of the present invention may include 0.1 wt % to 2 wt % of salt relative to the total weight of the composition.
[0076] As an example, the salt can be contained within a range consisting of a lower limit and / or an upper limit, relative to the total weight of the composition, the lower limit being selected from 0.5 wt % or more, 0.8 wt % or more, 1 wt % or more and 1.2 wt % or more, and the upper limit being selected from 1.9 wt % or less, 1.8 wt % or less, 1.7 wt % or less and 1.6 wt % or less.
[0077] The fermented product of the present invention may be a product in which a composition further comprising ginger is fermented.
[0078] As an exemplary embodiment, the composition to be fermented of the present invention may include 0.1 wt % to 1.5 wt % of ginger relative to the total weight of the composition.
[0079] As an example, ginger can be included within a range consisting of a lower limit selected from 0.3 wt % or more, 0.6 wt % or more, 0.9 wt % or more, and 1.1 wt % or more and / or an upper limit selected from 1.45 wt % or less, 1.4 wt % or less, 1.35 wt % or less, and 1.3 wt % or less, relative to the total weight of the composition.
[0080] The fermented product of the present invention may be a product in which a composition further comprising water is fermented.
[0081] In an exemplary embodiment of the present invention, after all raw materials included in the composition to be fermented of the present invention are mixed together, water may be added until the total weight of the composition becomes 100 weight %.
[0082] The fermented product of the present invention may contain any one or more selected from the culture of Leuconostoc mesenteroides CJLM119 strain, its lysate, its extract or its derived components.
[0083] In the present invention, the term "lysate" refers to a product obtained by disrupting the cell wall of a microorganism contained in a culture solution or a concentrate thereof by chemical or physical force. In the present invention, the term "lysate" can be used interchangeably with "disruption product".
[0084] In the present invention, the term "extract" refers to a substance obtained by removing microorganisms from a culture solution or a concentrate thereof.
[0085] Components derived from the strain of the present invention may include, for example, metabolites derived from the strain, and may include cytoplasmic fractions obtained by disrupting bacteria containing metabolites derived from the strain, etc. In addition, strain forms suitable for inclusion in food compositions, formulation methods, and methods for isolating strain-derived components are all well known to those skilled in the art.
[0086] In an exemplary embodiment of the present invention as described above, the fermented product of the present invention may be a product in which a composition including ingredients contained in kimchi paste (kimchi condiment) is fermented.
[0087] The food composition of the present invention may have an immune enhancing effect.
[0088] In the present invention, the term "immunoenhancement" refers to the effect of increasing the immune response in various specific or non-specific ways, and may further include immunomodulatory effects. The immunoenhancement effect may include, for example, the effect of resisting external pathogens, removing dead cells, and increasing the secretion of immune mediators by increasing the activity of macrophages, and may include the effect of increasing the activity of the immune system by increasing the activity of immunomodulatory factors, inhibiting the formation of new blood vessels, and preventing immune-related diseases by increasing the ability to inhibit pathogen growth.
[0089] Specifically, the immune enhancement effect can be achieved by increasing the secretion of immune mediators.
[0090] For example, the immune mediator may be a Th1 type proinflammatory cytokine, such as tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), and IL-1β, but is not limited thereto.
[0091] In an exemplary embodiment of the present invention, the composition of the present invention can increase the expression of TNF-α or IL-6.
[0092] The food composition of the present invention may have an intestinal health improving effect.
[0093] In the present invention, the term "intestinal health improvement" refers to the effect of maintaining the intestinal environment in a normal state by controlling the flora of beneficial bacteria and harmful bacteria in the intestine. The intestinal health improvement effect may include, for example, the effect of promoting the beneficial flora in the intestine and inhibiting the harmful bacterial flora, the effect of improving and activating the overall function of the intestine by enhancing the tight junction barrier function of the intestine, the effect of increasing the content of short-chain fatty acids in the intestine, and the effect of inducing the proliferation of intestinal epithelial cells, etc. In the present invention, "intestinal health improvement effect" can be used interchangeably with "intestinal regulation effect".
[0094] Specifically, the intestinal health improvement effect can be achieved by increasing the beneficial bacteria in the intestine and suppressing the harmful bacteria by inhibiting the growth of harmful bacteria.
[0095] The food composition of the present invention may have the effect of inhibiting the growth of harmful bacteria.
[0096] Harmful bacteria can be pathogenic microorganisms.
[0097] The pathogenic microorganisms are not particularly limited as long as they cause a specific disease upon infection, and may be, for example, Escherichia sp., Staphylococcus sp., Salmonella sp., Shigella sp., Klebsiella sp., Enterobacteriaceae sp., Pseudomonas sp., Moraxella sp., Helicobacter sp., Stenotrophomonas sp., Listeria sp., and Vibrio sp., and may be, for example, Escherichia coli, Staphylococcus aureus, Salmonella enteritidis, Salmonella typhi, Shigella dysenteriae, dysenteriae, Klebsiella pneumoniae, Pseudomonas aeruginosa, Moraxella catarrhalis, Helicobacter pylori, Stenotrophomonas maltophilia, Listeria monocytogenes, Vibrio cholerae and Vibrio vulnificus, and may specifically be Escherichia coli or Staphylococcus aureus, but is not limited thereto.
[0098] The food composition of the present invention may include a fermented product fermented with the composition for fermentation of the aforementioned aspects. For example, the fermented product may include a fermented product fermented with the Enterobacterium mesenteroides CJLM119 strain or its culture. Alternatively, the fermented product may include the following fermented product, wherein the fermented product fermented with the Enterobacterium mesenteroides CJLM119 strain or its culture is further fermented. As described above.
[0099] For example, the fermentation product may be in liquid form. In addition, the fermentation product may be a crude solution, which is a product obtained by fermentation or its supernatant.
[0100] The fermented product may be further subjected to additional fermentation. As an example, the fermented product of the present invention may be added to vegetables and the like and subjected to additional fermentation, or may be added to a liquid composition and the like and subjected to additional fermentation. Examples of vegetables include cabbage and radish, but are not limited thereto.
[0101] In the case where the fermentation product is a liquid fermentation product, the fermentation product of the present invention may include a liquid fermentation product and / or a fermentation product in which the liquid fermentation product is further fermented. At this time, the fermentation product obtained by further fermentation may be a liquid or solid fermentation product, but is not limited thereto.
[0102] In addition to the food composition, the food composition of the present invention may be in the form of a food additive, but is not limited thereto.
[0103] The food composition of the present invention may further comprise food additives, and unless otherwise specified, suitability as a "food additive" may be determined based on the specifications and standards of relevant items that comply with the general provisions of food additive regulations and general testing methods approved by the Food and Drug Administration.
[0104] Examples of items listed in the Food Additives Regulations include compounds (such as ketones, glycine, potassium citrate, niacin and cinnamic acid), natural additives (such as persimmon pigment, licorice extract, crystalline cellulose and guar gum) and mixed preparations (such as sodium L-glutamate preparations, noodle additive alkaline preparations, preservative preparations and tar pigment preparations).
[0105] Examples of the food of the present invention include: beverages such as fruit drinks, vegetable drinks, carbonated drinks, soy milk, yogurt and other lactic acid bacteria drinks, and mixed drinks; kimchi, kimchi sauce (kimchi condiment), fermented food; confectionery such as bread, rice cakes, dried fruits, candy, chocolate, chewing gum and jam, and ice cream products (such as ice cream, frozen desserts and ice cream powder); dairy products such as milk, low-fat milk, lactose-degraded milk, processed milk, goat milk, fermented milk, buttermilk, condensed milk, cream, butter, natural cheese, Processed cheese, milk powder and whey; meat products such as processed meat products, processed egg products and burgers; fish products such as processed fish products (such as fish cakes, ham, sausages and bacon); noodles such as ramen, dried noodles, fresh noodles, fried noodles, deluxe dried noodles, improved cooked noodles, frozen noodles and pasta; seasonings such as soy sauce, soybean paste, red pepper paste, chunjang, cheonggukjang, mixed sauce, vinegar, seasoning sauce, ketchup, curry and dressing, but not limited to.
[0106] In addition to the above, the food composition of the present invention can include various nutrients, vitamins, electrolytes, flavoring agents, coloring agents, pectin acid and its salts, alginic acid and its salts, organic acids, protective colloid thickeners, pH regulators, stabilizers, preservatives, glycerol, alcohols, carbonating agents used in carbonated beverages, etc. In addition, the food composition of the present invention can include natural fruit juice and pulp for the production of fruit juice drinks and vegetable beverages. These ingredients can be used alone or in combination.
[0107] Another aspect of the present invention provides a health functional food for immunity enhancement, which comprises a fermentation product fermented with the Leuconostoc mesenteroides CJLM119 strain or a culture thereof.
[0108] Another aspect of the present invention provides a health functional food for improving intestinal health, which comprises a fermentation product fermented with the Leuconostoc mesenteroides CJLM119 strain or a culture thereof.
[0109] The strain and culture of Leuconostoc mesenteroides CJLM119 were as described above.
[0110] The fermented product of the present invention may be a product fermented at 32° C. to 42° C. for 10 to 30 hours using any one or more selected from the strain of the present invention or a culture thereof, and as described above.
[0111] The fermented product of the present invention may be a product in which a composition comprising any one or more selected from garlic, red pepper powder, and a nitrogen source is fermented, and as described above.
[0112] The fermented product may be a product in which a composition comprising 5 wt% to 9 wt% of garlic relative to the total weight of the composition is fermented, and as described above.
[0113] The fermented product of the present invention may be a product in which a composition further comprising any one or more selected from a carbon source or a salt is fermented, and as described above.
[0114] The fermented product of the present invention may comprise any one or more selected from the culture of Leuconostoc mesenteroides CJLM119 strain, its lysate, its extract or its derived components, and as described above.
[0115] In the present invention, the term "health functional food" refers to food that complies with the "Health Functional Food Law" (Article 3, paragraph 1) and is manufactured and processed using raw materials or ingredients with functional properties that are beneficial to the human body, and "functionality" means adjusting nutrients according to the structure and function of the human body or obtaining effects that are beneficial to health, such as physiological effects (Article 3, paragraph 2).
[0116] The health functional food of the present invention may be in the form of a food additive.
[0117] When the health functional food of the present invention is used as a food additive, the health functional food can be added as a composition or used together with other foods or food ingredients, and can be used appropriately according to a conventional method. The active ingredient can be used appropriately according to its purpose of use (prevention or improvement). Usually, when manufacturing food or beverages, relative to the amount of raw materials, the addition amount of the health functional food composition of the present invention is 15 weight portions or less, preferably 10 weight portions or less. However, in the case of long-term intake for health purposes, the amount can be equal to or less than the above range, and because there is no problem in terms of safety, the use amount of the active ingredient can be equal to or greater than the above range.
[0118] The health functional food may further contain food additives, and as described above.
[0119] Another aspect of the present invention provides a feed composition for enhancing immunity, comprising a fermentation product fermented with the Leuconostoc mesenteroides CJLM119 strain or a culture thereof.
[0120] Another aspect of the present invention provides a feed composition for improving intestinal health, comprising a fermentation product fermented with the Leuconostoc mesenteroides CJLM119 strain or a culture thereof.
[0121] The strain and culture of Leuconostoc mesenteroides CJLM119 were as described above.
[0122] The fermented product of the present invention may be a product fermented at 32° C. to 42° C. for 10 to 30 hours using any one or more selected from the strain of the present invention or a culture thereof, and as described above.
[0123] The fermented product of the present invention may be a product in which a composition comprising any one or more selected from garlic, red pepper powder and a nitrogen source is fermented, and as described above.
[0124] The fermented product may be a product in which a composition comprising 5 to 9 wt % of garlic, relative to the total weight of the composition, is fermented, and as described above.
[0125] The fermented product of the present invention may be a product in which a composition further comprising any one or more selected from a carbon source or a salt is fermented, and as described above.
[0126] The fermented product of the present invention may comprise any one or more selected from the culture of Leuconostoc mesenteroides CJLM119 strain, its lysate, its extract or its derived components, and as described above.
[0127] In addition to the feed composition, the feed composition of the present invention may be in the form of a feed additive composition.
[0128] In the case where the composition of the present invention is prepared as a feed additive, the composition can be a 20% to 90% highly concentrated liquid or can be prepared in the form of a powder or granules. The feed additive may further contain any one or more of the following: organic acids, such as citric acid, fumaric acid, adipic acid, lactic acid and malic acid; phosphates, such as sodium phosphate, potassium phosphate, acid pyrophosphate and polyphosphate (polymeric phosphate); and natural antioxidants, such as polyphenols, catechins, α-tocopherol, rosemary extract, vitamin C, green tea extract, licorice extract, chitosan, tannic acid and phytic acid. In the case of being prepared as a feed, the composition can be formulated in the form of a common feed and can contain common feed ingredients together.
[0129] Feed and feed additives may further include: cereals, such as ground or cracked wheat, oats, barley, corn and rice; plant protein feeds, such as feeds containing rapeseed, soybeans and sunflower; animal protein feeds, such as blood meal, meat meal, bone meal and fish meal; and dry ingredients, such as sugar and dairy products, such as various milk powders and whey powders; in addition, they may also include nutritional supplements, digestion and absorption enhancers, growth promoters, etc.
[0130] Feed additives can be applied to animals alone, or mixed with other feed additives in edible carriers and applied to animals. By mixing feed additives directly into animal feed, or in an oral dosage form separated from feed, feed additives can be easily applied to animals as supplementary additives (top dressing). In the case where feed additives are applied separately from animal feed, feed additives can be combined with pharmaceutically acceptable edible carriers to prepare quick-release or sustained-release preparations known in the art. Such edible carriers can be solid or liquid, such as corn starch, lactose, sucrose, soybean flakes, peanut oil, olive oil, sesame oil and propylene glycol. In the case of using solid carriers, feed additives can be supplementary additives in tablets, capsules, powders, lozenges or sugary tablets or micro-dispersed forms. In the case of using liquid carriers, feed additives can be gelatin soft capsules, or the preparations of syrups, suspensions, emulsions or solutions.
[0131] Feed and feed additives may contain adjuvants, such as preservatives, stabilizers, wetting agents or emulsifiers and solution promoters. Feed additives can be added to animal feed by injection, spraying or mixing and used.
[0132] The feed or feed additive of the present invention can be applied to the diet of a variety of animals including mammals, poultry and fish.
[0133] The feed or feed additive of the present invention can be used for mammals, such as pigs, cattle, horses, sheep, rabbits, goats, rodents and laboratory rodents (such as rats, hamsters and guinea pigs) and companion animals (e.g., dogs and cats), for poultry, such as chickens, turkeys, ducks, geese, pheasants and quail, and for fish, such as carp, crucian carp and trout, but is not limited thereto.
[0134] Another aspect of the present invention provides a method for preparing a composition for immune enhancement, the method comprising fermenting a composition comprising any one or more selected from garlic, red pepper powder and a nitrogen source with the Leuconostoc mesenteroides CJLM119 strain or a culture thereof.
[0135] Another aspect of the present invention provides a method for preparing a composition for improving intestinal health, the method comprising fermenting a composition comprising any one or more selected from garlic, red pepper powder and a nitrogen source with the Leuconostoc mesenteroides CJLM119 strain or a culture thereof.
[0136] The strain and culture of Leuconostoc mesenteroides CJLM119 were as described above.
[0137] The composition prepared according to the method of the present invention may be a fermentation product.
[0138] The fermented product of the present invention may be a product fermented at 32° C. to 42° C. for 10 to 30 hours using any one or more selected from the strains of the present invention or cultures thereof, as described above.
[0139] The fermented product may be a product in which a composition comprising 5 to 9 wt % of garlic, relative to the total weight of the composition, is fermented, and as described above.
[0140] The fermented product of the present invention may be a product in which a composition further comprising any one or more selected from a carbon source or a salt is fermented, and as described above.
[0141] The fermented product of the present invention may comprise any one or more selected from the culture of Leuconostoc mesenteroides CJLM119 strain, its lysate, its extract or its derived components, and as described above.
[0142] Another aspect of the present invention provides a method for increasing the immune enhancement effect of a composition, the method comprising fermenting the composition with the Leuconostoc mesenteroides CJLM119 strain or a culture thereof.
[0143] Another aspect of the present invention provides a method for increasing the intestinal health improvement effect of a composition, the method comprising fermenting the composition with the Leuconostoc mesenteroides CJLM119 strain or a culture thereof.
[0144] The strain, culture, immune enhancement and intestinal health improvement of Leuconostoc mesenteroides CJLM119 are as described in the previous aspects.
[0145] [Mode for carrying out the present invention]
[0146] Hereinafter, the present invention will be described in more detail with reference to Examples. However, the following examples are only for illustrating preferred embodiments of the present invention, and are therefore not intended to limit the scope of the present invention thereto. Meanwhile, technical matters not described in this specification can be fully understood and easily implemented by those skilled in the art of the present invention or similar technical fields. In addition, many papers and patent documents are also cited in this specification, and citations are pointed out. The disclosures of the cited papers and patent documents are incorporated into this specification as a whole by reference, so as to more clearly explain the content of the present invention and the level of the technical field to which the present invention belongs.
[0147] Preparation Example: Preparation of Fermentation Composition
[0148] First, the compositions were prepared separately by mixing the raw materials except the strain according to the following Table 1. When preparing the compositions, 7 wt % of garlic, 1.2 wt % of ginger, 2 wt % of red pepper powder, 3 wt % of a carbon source (crystalline fructose), 1.5 wt % of salt, and 1.2 wt % of a seasoning ( TNR, CJ CheilJedang), and mixed them together. Next, 2 wt% of the intestinal membrane-like Leuconostoc CJLM119 strain (preservation number KCTC13043BP, US 2019-0297908 A1) or intestinal membrane-like Leuconostoc KCTC 3505 was added, water was added until the total weight was 100 wt%, mixed, and then cultured at 30 ° C for 20 hours for fermentation, thereby preparing the fermentation compositions of Preparation Examples 1 to 4 and Comparative Examples 1 to 3. After fermentation, the bacterial count of the intestinal membrane-like Leuconostoc CJLM119 strain in each fermentation composition was 2×10 8 cfu / mL.
[0149] After fermentation was completed, the supernatant of the fermentation composition was obtained by centrifuging the fermentation composition at 13000 rpm for 5 minutes and filtering the supernatant through a 0.45 μm syringe filter to remove bacteria. The strain of Leuconostoc mesenteroides in the fermentation composition was always 10 8 cfu / mL or more.
[0150] [Table 1]
[0151]
[0152]
[0153] Example 1: Testing the cytotoxicity of the fermentation composition
[0154] The cytotoxicity of each fermentation composition was tested using the WST-1 assay (Roche).The WST-1 assay was performed using the Cell Proliferation Reagent WST-1 Assay Kit (Roche, USA) according to the manufacturer's instructions.
[0155] Specifically, the mouse macrophage cell line J774A.1 obtained from the Korean Cell Line Bank (KCLB) was used as an animal cell. The cells were cultured at 37°C in the presence of 5% CO2 using DMEM (Gibco, USA) supplemented with heat-inactivated 10% fetal bovine serum (FBS), 1% L-glutamine, penicillin G (100 IU / mL) and streptomycin (100 mg / mL). The cells were plated at 5×10 4 Cells / well (volume 150 μL) were dispensed into a 96-well plate (Corning, USA), cultured for about 3 hours until the cells completely formed a monolayer, and used for experiments.
[0156] 1-1. Cytotoxicity of fermentation composition according to materials
[0157] The fermentation compositions of Preparation Examples 1 to 3 and Comparative Examples 1 and 2 were diluted with DMEM medium without antibiotic supplementation and dispensed into 96-well plates at 100 μL. As controls, DMEM medium without antibiotic supplementation (negative control) or DMEM medium supplemented with 1 μg / mL lipopolysaccharide (LPS) and without antibiotic supplementation (positive control) were dispensed into 96-well plates at 100 μL. J774A.1 cells were inoculated so that 3.3×10 cells were present in each fermentation composition or control. 5 The 96-well plate was incubated at 37°C in the presence of 5% CO2 for 24 hours.
[0158] After the culture was completed, the cell supernatant was removed, WST-1 was diluted to 10% with DMEM, and 100 μL was dispensed into each well and cultured at 37°C for 1 hour in the presence of 5% CO 2 . Thereafter, the absorbance was measured at 500 nm using a spectrophotometer (BioTek, USA).
[0159] As a result, in all cells treated with the fermentation compositions of Preparation Examples 1 to 3 and Comparative Examples 1 and 2, cell viability increased compared to the negative control, and it was found that the fermentation compositions did not show cytotoxicity ( Figure 1 ).
[0160] 1-2. Cytotoxicity of the fermentation composition
[0161] The fermentation composition of Example 4 was prepared by diluting the DMEM medium without antibiotics, so that the Leuconostoc mesenteroides CJLM119 strain in the fermentation composition was 5×10 6 cfu / mL (fermentation composition A), 10 6 cfu / mL (fermentation composition B) and 5×10 5 cfu / mL (fermentation composition C), and these were dispensed into 96-well plates in 100 μL. The supernatants of fermentation compositions A to C were diluted with DMEM without antibiotics at the same dilution factor, and these were dispensed into 96-well plates in 100 μL. As a control, DMEM medium without antibiotics (negative control) or DMEM medium supplemented with 1 μg / mL LPS and without antibiotics (positive control) was dispensed into 96-well plates in 100 μL. J774A.1 cells were inoculated to make 3.3×10 in each fermentation composition, its supernatant or each control. 5 The 96-well plate was incubated at 37°C for 24 hours in the presence of 5% CO2. After the incubation, the absorbance was measured at 500 nm using a spectrophotometer in the same manner as in Example 1-1.
[0162] As a result, the 6 cfu / mL (fermentation composition A), 10 6 cfu / mL (fermentation composition B) and 5×10 5 cfu / mL (fermentation composition C) In cells treated with the fermentation composition of the enteric-like Leuconostoc mesenteroides CJLM119 strain and its supernatant, cell viability was maintained, and it was found that the fermentation composition and its supernatant did not show cytotoxicity ( Figure 2 ).
[0163] 1-3. Cytotoxicity of fermentation composition according to fermentation strain
[0164] The fermentation composition of Example 4 was prepared by diluting the DMEM medium without antibiotic supplementation, so that the Leuconostoc mesenteroides CJLM119 strain in the fermentation composition was 1.25×10 6 cfu / mL, 2.5×10 6 cfu / mL, 5.0×10 6 cfu / mL and 6.25×10 6 cfu / mL, and these strains were dispensed into 96-well plates at 100 μL. Comparative Example 3 was diluted with DMEM medium without antibiotic supplementation, so that the enteric-like Leuconostoc KCTC 3505 strain in the fermentation composition was 1.25×10 6 cfu / mL, 2.5×10 6 cfu / mL, 5.0×106 cfu / mL and 6.25×10 6 cfu / mL, and these were dispensed into 96-well plates in 100 μL. As controls, DMEM medium without antibiotic supplementation (negative control) or DMEM medium supplemented with 1 μg / mL LPS and without antibiotic supplementation (positive control) was dispensed into 96-well plates in 100 μL. J774A.1 cells were inoculated so that 3.3×10 5 The 96-well plate was incubated at 37°C for 24 hours in the presence of 5% CO2. After the incubation, the absorbance was measured at 500 nm using a spectrophotometer in the same manner as in Example 1-1.
[0165] As a result, the 6 cfu / mL and 6.25×10 6 cfu / mL In all cells treated with the fermentation composition of Leuconostoc mesenteroides CJLM119 or KCTC 3505 strain, cell viability increased compared to the negative control, and it was found that the fermentation composition did not show cytotoxicity ( Figure 3 ).
[0166] In addition, the 6 cfu / mL, 2.5×10 6 cfu / mL and 5.0×10 6 cfu / mL In all cells treated with the fermentation composition of Leuconostoc mesenteroides CJLM119 or KCTC 3505 strain, cell viability increased compared to the negative control, and it was found that the fermentation composition did not show cytotoxicity ( Figure 4 ).
[0167] Example 2: Detection of the immune enhancement effect of the fermentation composition
[0168] In order to evaluate the immune enhancement effect of the fermented compositions of Preparation Examples 1 to 4, the ability of the fermented compositions to secrete tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6), Th1 type proinflammatory cytokines, was detected by ELISA assay.
[0169] 2-1. Immunoenhancing effect of fermented composition according to materials
[0170] The fermentation compositions of Examples 1 to 3 and Comparative Examples 1 and 2 were diluted with DMEM medium without antibiotic supplementation and dispensed into 96-well plates at 100 μL. As controls, DMEM medium without antibiotic supplementation (negative control) or DMEM medium supplemented with 1 μg / mL LPS and without antibiotic supplementation (positive control) was dispensed into 96-well plates at 100 μL. J774A.1 cells were inoculated to give 3.3×10 cells per fermentation composition or control. 5 The 96-well plate was incubated at 37°C in the presence of 5% CO2 for 24 hours.
[0171] After the culture was completed, the culture solution was centrifuged at 1400 rpm for 10 minutes to obtain the cell supernatant, from which J774A.1 cells and intestinal membrane-like Leuconostoc strains were removed. ELISA was determined using DuoSet ELISA Auxiliary Kit 2 (R&D systems, Catalog No. DY008, USA). According to the manufacturer's instructions, a mouse TNF-α DuoSet ELISA kit (R&D systems, Catalog No. DY 406-05, USA) containing TNF-α antibody and biotinylated TNF-α antibody (secondary antibody) and a mouse IL-6 DuoSet ELISA kit (R&D systems, Catalog No. DY 410-05, USA) containing IL-6 antibody and biotinylated IL-6 antibody (secondary antibody) were used. ELISA plates were coated with TNF-α capture antibody (R&D systems, Catalog No. 840143) and IL-6 capture antibody (R&D systems, Catalog No. 840171) at room temperature for 24 hours. Thereafter, 100 μL of cell supernatant and TNF-α standard solution (R&D systems, Cat. No. 840145) or IL-6 standard solution (R&D systems, Cat. No. 840173) were diluted with reaction diluent (R&D systems, Cat. No. DY995), 100 μL was added to the plate, and incubated at room temperature for 2 hours. After that, the culture medium was removed, and biotinylated TNF-α antibody (R&D systems, Cat. No. 840144) and biotinylated IL-6 antibody (R&D systems, Cat. No. 840172) (secondary antibodies) were added, and the plate was coated for 2 hours at room temperature. The color reaction was induced by streptavidin-conjugated horseradish peroxidase (R&D systems, Cat. No. 893975) and its substrate TMB (tetramethylbenzidine, R&D systems, Cat. No. DY999). After the color reaction was carried out, 50 μL of stop solution (2N H2SO4) was added to each well to stop the reaction. At this time, the color reaction changes from blue to yellow. After the color reaction is completed, the absorbance is measured at 470 nm using a spectrophotometer (calibrated value 540 nm).
[0172] As a result, in the cells treated with the fermentation compositions of Preparation Examples 1 to 3 and Comparative Examples 1 and 2, TNF-α ( Figure 5 ) and IL-6 ( Figure 6 ) was significantly increased (***p<0.001).
[0173] In particular, in the case of the fermented composition of Preparation Example 1 obtained by fermenting a composition containing garlic with the Enterobacterium mesenteroides CJLM119 strain, the expression of TNF-α and IL-6 was significantly increased compared with the case of other fermented compositions, and it was found that the fermented composition of Preparation Example 1 exhibited an excellent immunoenhancing effect, and the expression of TNF-α and IL-6 was significantly improved compared with the case of Comparative Example 2, in which the composition containing garlic was not fermented with the Enterobacterium mesenteroides CJLM119 strain.
[0174] Specifically, if Figure 5 As shown, the expression of IL-6 was higher in the cells treated with Comparative Example 2, in which the composition comprising garlic was not fermented with the Enterobacterium mesenteroides CJLM119 strain, than in the cells treated with other fermentation compositions and the control, but the expression of IL-6 increased by about two times in the cells treated with Preparation Example 1, in which the composition comprising garlic was fermented with the Enterobacterium mesenteroides CJLM119 strain, and it was found that the composition fermented with the Enterobacterium mesenteroides CJLM119 strain showed a significantly excellent immune enhancement effect.
[0175] 2-2. Immunoenhancing effect of fermented composition
[0176] The fermentation composition of Example 4 was prepared by diluting the DMEM medium without antibiotics, so that the Leuconostoc mesenteroides CJLM119 strain in the fermentation composition was 5×10 6 cfu / mL, 10 6 cfu / mL and 5×10 5 cfu / mL, and these were aliquoted into 96-well plates in 100 μL portions. J774A.1 cells were inoculated so that 3.3×10 5 The 96-well plate was incubated at 37°C for 24 hours in the presence of 5% CO2. After the incubation, a color reaction was performed in the same manner as in Example 2-1, and then the absorbance was measured at 470 nm (corrected value 540 nm) using a spectrophotometer.
[0177] As a result, the 6 cfu / mL, 10 6 cfu / mL and 5×105 cfu / mL of the fermentation composition of Leuconostoc mesenteroides CJLM119 strain, compared with the negative control, TNF-α( Figure 7 ) and IL-6 ( Figure 8 ) expression was significantly increased or similar to that of the negative control (***p<0.001, **p<0.01).
[0178] In particular, in the case of 5×10 6 In the case of the fermentation composition A of the enteric-like Leuconostoc CJLM119 strain, the expression of TNF-α and IL-6 was significantly increased compared with the cases of other fermentation compositions, and it has been found that the fermentation composition A exhibits an excellent immunoenhancing effect.
[0179] 2-3. Immunoenhancing effect of fermentation composition based on fermentation strain
[0180] The fermentation composition of Example 4 was prepared by diluting the DMEM medium without antibiotics, so that the content of the Leuconostoc mesenteroides CJLM119 strain in the fermentation composition was 1.25×10 6 cfu / mL, 2.5×10 6 cfu / mL, 5.0×10 6 cfu / mL and 6.25×10 6 cfu / mL, and these were dispensed into 96-well plates in 100 μL portions. Comparative Example 3 was diluted with DMEM medium not supplemented with antibiotics so that the Leuconostoc mesenteroides KCTC 3505 strain in the fermentation composition was 1.25×10 6 cfu / mL, 2.5×10 6 cfu / mL, 5.0×10 6 cfu / mL and 6.25×10 6 cfu / mL, and these were dispensed into 96-well plates in 100 μL. As controls, DMEM medium without antibiotic supplementation (negative control) or DMEM medium supplemented with 1 μg / mL LPS and without antibiotic supplementation (positive control) was dispensed into 96-well plates in 100 μL. J774A.1 cells were inoculated so that 3.3×10 5 The 96-well plate was incubated at 37°C for 24 hours in the presence of 5% CO2. After the incubation, a color reaction was performed in the same manner as in Example 2-1, and then the absorbance was measured at 470 nm (corrected value 540 nm) using a spectrophotometer.
[0181] As a result, the 6 cfu / mL and 6.25×10 6cfu / mL of the fermentation composition of Leuconostoc mesenteroides CJLM119 strain, compared with the negative control, TNF-α( Fig. 9 ) and IL-6 ( Fig.11 ) expression was significantly increased (***p<0.001). 6 cfu / mL and 6.25×10 6 cfu / mL of the fermentation composition of Leuconostoc mesenteroides KCTC3505 strain, compared with the fermentation composition of LM119 (1.25×10 6 cfu / mL and 6.25×10 6 cfu / mL), and the expression of TNF-α was significantly decreased compared with that of cells treated with LM119 fermentation composition (1.25×10 6 cfu / mL)-treated cells, the expression of IL-6 was significantly decreased ( Fig. 9 and Fig.11 , ##p<0.01, #p<0.05).
[0182] In addition, the 6 cfu / mL, 2.5×10 6 cfu / mL and 5.0×10 6 cfu / mL of the fermentation composition of Leuconostoc mesenteroides CJLM119 or KCTC 3505 strains, compared with the negative control, TNF-α ( Fig.10 ) and IL-6 ( Fig.12 ) expression was significantly increased (***p<0.001, **p<0.01, *p<0.05). 6 cfu / mL of the fermentation composition of Leuconostoc mesenteroides KCTC 3505 strain, the expression of TNF-α was significantly lower than that of the fermentation composition of LM119 (2.5×10 6 cfu / mL), the expression of IL-6 was significantly lower than that of cells treated with LM119 fermentation composition (2.5×10 6 cfu / mL and 5.0×10 6 cfu / mL) treated cells ( Fig.10 and Fig.12 , ***p<0.001, **p<0.01, *p<0.05).
[0183] Example 3: Detection of the inhibitory effect of the fermentation composition based on the material on the growth of harmful bacteria
[0184] In order to examine the effect of inhibiting the growth of harmful bacteria in the fermentation composition of Preparation Example 4, Escherichia coli and Staphylococcus aureus (known as pathogenic microorganisms of bacteria causing food poisoning) were inoculated into BHI (brain heart infusion) broth medium (BDDIFCO) respectively, and cultured at 37°C for 24 hours to obtain cultures. The fermentation composition of Preparation Example 4 was diluted with BHI broth medium to make the concentrations 0%, 25%, 40% and 50% (v / v), thereby preparing a culture medium. The diluted culture medium was dispensed into 96-well plates in 200 μl, and 1×10 6 E. coli and Staphylococcus aureus strains were inoculated with 10 cells / well. The 96-well plate was incubated at 37°C for 24 hours. After incubation, the OD 600 By comparing the OD in the medium containing 0% fermentation composition 600 The values were compared with the OD values in the diluted culture medium containing 25%, 40% or 50% (v / v) of the fermentation composition. 600 The growth inhibition rate (%) of harmful bacteria at each concentration of the fermentation composition was determined by the following formula: OD of the diluted culture medium of each uninoculated strain 600 Value as blank.
[0185] Inhibition rate (%) = [1-(OD of the experimental group after inoculation and culture) 600 ) – OD of the experimental group after the strain was not inoculated and cultured 600 ) / (OD of the control after inoculation and culture 600 )-(OD of the control after culture without inoculation of strains 600 )]×100(%)
[0186] As a result, the fermented composition of Preparation Example 1 showed a growth inhibition rate of up to 90% or more against the food poisoning bacteria Escherichia coli and Staphylococcus aureus at all concentrations ( Fig.13 ).
[0187] Based on the above description, it will be appreciated by those skilled in the art that the present invention can be implemented in different specific forms without changing its technical spirit or basic features. Therefore, it should be understood that the above embodiments are not restrictive in all aspects, but illustrative. The scope of the present invention is defined by the appended claims, rather than by the previous description, and therefore all changes and modifications falling within the limits of the claims or the equivalents of such limits are intended to be covered by the claims.
[0188]
Claims
1. A composition for fermentation, comprising any one or more selected from the strain of Leuconostocmesenteroides CJLM119 or a culture thereof.
2. A food composition for immune enhancement, comprising a fermentation product fermented with the Leuconostoc mesenteroides CJLM119 strain or a culture thereof.
3. A food composition for improving intestinal health, comprising a fermentation product fermented with the Leuconostoc mesenteroides CJLM119 strain or a culture thereof.
4. The food composition according to claim 2 or 3, wherein the fermented product is a product in which a composition comprising any one or more selected from garlic, red pepper powder and a nitrogen source is fermented.
5. The food composition according to claim 2 or 3, wherein the fermented product is a product in which a composition comprising 5 to 9 wt% of garlic relative to the total weight of the composition is fermented.
6. The food composition of claim 2 or 3, wherein the food composition increases the expression of TNF-α or IL-6.
7. The food composition of claim 2 or 3, wherein the food composition inhibits the growth of harmful bacteria.
8. The food composition according to claim 7, wherein the harmful bacteria is any one or more selected from the group consisting of Escherichia sp., Staphylococcus sp., Salmonella sp., Shigella sp., Klebsiella sp., Enterobacteriaceae sp., Pseudomonas sp., Moraxella sp., Helicobacter sp., Stenotrophomonas sp., Listeria sp., and Vibrio sp.
9. The food composition according to claim 2 or 3, wherein the fermented product is a product fermented at 32°C to 42°C for 10 to 30 hours.
10. The food composition according to claim 2 or 3, wherein the fermented product is a product in which a composition further comprising any one or more selected from a carbon source or a salt is fermented.
11. The food composition according to claim 2 or 3, wherein the fermented product comprises any one or more selected from the culture of Leuconostoc mesenteroides CJLM119 strain, its lysate, its extract or its derived components.
12. The food composition according to claim 2 or 3, wherein the fermented product comprises a fermented product fermented with the Leuconostoc mesenteroides CJLM119 strain or a culture thereof; or the following fermented product, wherein the fermented product is further fermented.
13. A health functional food for immunity enhancement, comprising a fermentation product fermented with the Leuconostoc mesenteroides CJLM119 strain or a culture thereof.
14. A health functional food for improving intestinal health, comprising a fermentation product fermented with the Leuconostoc mesenteroides CJLM119 strain or a culture thereof.
15. The health functional food according to claim 12 or 13, wherein the fermented product is a product in which a composition comprising any one or more selected from garlic, red pepper powder and a nitrogen source is fermented. 16 . The health functional food according to claim 12 , wherein the fermented product is a product in which a composition comprising 5 to 9 wt % of garlic relative to the total weight of the composition is fermented.
17. The health functional food according to claim 12 or 13, wherein the fermented product comprises a fermented product fermented with Leuconostoc mesenteroides CJLM119 strain or a culture thereof; or the following fermented product, wherein the fermented product is further fermented.
18. A method for increasing the immune-enhancing effect of a composition, the method comprising fermenting the composition with the Leuconostoc mesenteroides CJLM119 strain or a culture thereof.
19. A method for enhancing the intestinal health improvement effect of a composition, the method comprising fermenting the composition with the Leuconostoc mesenteroides CJLM119 strain or a culture thereof.
20. The method according to claim 18 or 19, wherein the composition further comprises any one or more selected from garlic, red pepper powder and a nitrogen source.
21. The method of claim 18 or 19, wherein the composition is a food composition.
Citation Information
Cited By
Soil conditioner for improving saline-alkali soil as well as preparation method and application of soil conditioner
CN119177260A
